Smoldering Multiple Myeloma Clinical Trials

60 clinical trials for Smoldering Multiple Myeloma across international registries, including 21 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Immuno-PRISM (PRecision Intervention Smoldering Myeloma) — RECRUITING · PHASE2
• CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study — RECRUITING
• A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma — RECRUITING · PHASE2
• Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome — RECRUITING
• FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease — RECRUITING · NA
• Development of novel minimally-invasive methods to determine the risk of progression for patients with smoldering multiple myeloma via longitudinal characterization of tumor cells and immune cells — RECRUITING
• Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution — RECRUITING
• A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) — RECRUITING · NA
• Promoting Diagnosis and Management of AL in Italy (ProDigALIty) — RECRUITING
• Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions — RECRUITING
• A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple Myeloma — RECRUITING · NA
• Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial — RECRUITING
• European Myeloma Network (EMN) Sample Project — RECRUITING
• Registry for Adults With Plasma Cell Disorders (PCD's) — RECRUITING
• Screening for AL Amyloidosis in Smoldering Multiple Myeloma — RECRUITING
• The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma — RECRUITING · PHASE1
• Whole Body MRI in Oncology — RECRUITING
• Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma — RECRUITING · PHASE2
• Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma — RECRUITING · PHASE2
• A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH — RECRUITING
• A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) — RECRUITING · PHASE2
• A study of carfilzomib, lenalidomide and dexamethasone (KRd) plus high-dose therapy with melphalan-200 and autologous stem cell transplantation, followed by consolidation with KRd, and maintenance with lenalidomide and dexamethasone in patients with high risk smoldering multiple myeloma (SMM) under 65 years — ACTIVE_NOT_RECRUITING · PHASE2
• Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE3
• Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant — ACTIVE_NOT_RECRUITING · PHASE3
• Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics — NOT_YET_RECRUITING
• A Real-world Study in Participants With Smoldering Multiple Myeloma — COMPLETED
• Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program — ACTIVE_NOT_RECRUITING · NA
• Denosumab for Smoldering Multiple Myeloma — COMPLETED · PHASE2
• A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma — COMPLETED · PHASE3
• Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma — COMPLETED · PHASE2
• Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer — COMPLETED · PHASE2
• Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders — ACTIVE_NOT_RECRUITING
• A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE2
• Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM — ACTIVE_NOT_RECRUITING · PHASE1
• CAR- PRISM (PRecision Intervention Smoldering Myeloma) — ACTIVE_NOT_RECRUITING · PHASE2
• Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE2
• Imaging in MGUS, SMM and MM — COMPLETED · PHASE2
• A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) — ACTIVE_NOT_RECRUITING · NA
• Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma — COMPLETED · PHASE2
• Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma — COMPLETED · PHASE1
• Screening to Improve Survival in AL Amyloidosis — COMPLETED
• Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations. — ACTIVE_NOT_RECRUITING · NA
• Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma — COMPLETED · PHASE2
• E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma — COMPLETED · PHASE2
• A Phase II Study of BI-505 in Smoldering Multiple Myeloma — TERMINATED · PHASE2
• Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE2
• PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma — TERMINATED · PHASE2
• MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey — OTHER

Refine this search